Tokyo, July 13, 2006 (JCN) - Takeda Pharmaceutical has announced that its investigational compound TAK-491 has entered into the Phase II clinical stage in the US and Europe. An angiotensin receptor blocker (ARB) discovered by Takeda, TAK-491 helps lower blood pressure by suppressing the action of vasopressor hormone Angiotensin II.
